Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypic correction of murine hemophilia A using an iPS cell-based therapy.

Proceedings of the National Academy of Sciences of the United States of America - 20 Jan 2009

Xu Dan, Alipio Zaida, Fink Louis M, Adcock Dorothy M, Yang Jianchang, Ward David C, Ma Yupo

Abstract excerpt

Hemophilia A is caused by mutations within the Factor VIII (FVIII) gene that lead to depleted protein production and inefficient blood clotting. Several attempts at gene therapy have failed for various reasons-including immune rejection. The recent generation of induced pluripotent stem (iPS) cells from somatic cells by the ectopic expression of 3 transcription factors, Oct4, Sox2, and Klf4, provides a means of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Endothelial Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Fibroblasts

Share to Hemophilia A

Share to Kruppel-Like Factor 4

Share to Platelet Endothelial Cell Adhesion Molecule-1

Share to Pluripotent Stem Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 19139414
DOI: 10.1073/pnas.0812090106
PMCID: PMC2630078

Genes

SALL4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypic correction of murine hemophilia A using an iPS cell-based therapy.PMID 19139414Read ↗

Patient-Specific iPSC-Derived Endothelial Cells Provide Long-Term Phenotypic Correction of Hemophilia ASemantic proximity Read ↗

Endothelial cells derived from patients’ induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia ASemantic proximity Read ↗

Restoration of FVIII Function and Phenotypic Rescue in Hemophilia A Mice by Transplantation of MSCs Derived From F8-Modified iPSCsSemantic proximity Read ↗

Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCsSemantic proximity Read ↗

Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.Semantic proximity Read ↗

Long-term correction of hemophilia A via integration of a functionally enhanced FVIII gene into the AAVS1 locus by nickase in patient-derived iPSCsSemantic proximity Read ↗

ssODN-Mediated In-Frame Deletion with CRISPR/Cas9 Restores FVIII Function in Hemophilia A-Patient-Derived iPSCs and ECsSemantic proximity Read ↗

Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.Semantic proximity Read ↗

Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells.Semantic proximity Read ↗

Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 systemSemantic proximity Read ↗

Phenotypic correction and stable expression of factor VIII in hemophilia A mice by embryonic stem cell therapy.Semantic proximity Read ↗

Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable deviceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.